RESUMEN
AIMS/HYPOTHESIS: Glucokinase activators (GKAs) are currently being developed as new therapies for type 2 diabetes and have been shown to enhance beta cell survival and proliferation in vitro. Here, we report the effects of chronic GKA treatment on the development of hyperglycaemia and beta cell loss in the male Zucker diabetic fatty (ZDF) rat, a model of type 2 diabetes with severe obesity. METHODS: Cell protection by GKA was studied in MIN6 and INS-1 cells exposed to hydrogen peroxide. Glucose homeostasis and beta cell mass were evaluated in ZDF rats dosed for 41 days with Cpd-C (a GKA) or glipizide (a sulfonylurea) as food admixtures at doses of approximately 3 and 10 mg kg(-1) day(-1). RESULTS: Incubation of MIN6 and INS-1 832/3 insulinoma cell cultures with GKA significantly reduced cell death and impairment of intracellular NADH production caused by exposure to hydrogen peroxide. Progression from prediabetes (normoglycaemia and hyperinsulinaemia) to overt diabetes (hyperglycaemia and hypoinsulinaemia) was significantly delayed in male ZDF rats by in-feed treatment with Cpd-C, but not glipizide. Glucose tolerance, tested in the fifth week of treatment, was also significantly improved by Cpd-C, as was pancreatic insulin content and beta cell area. In a limited immunohistochemical analysis, Cpd-C modestly and significantly enhanced the rate of beta cell proliferation, but not rates of beta cell apoptosis relative to untreated ZDF rats. CONCLUSIONS/INTERPRETATION: These findings suggest that chronic activation of glucokinase preserves beta cell mass and delays disease in the ZDF rat, a model of insulin resistance and progressive beta cell failure.
Asunto(s)
Diabetes Mellitus Tipo 2/prevención & control , Activadores de Enzimas/farmacología , Glucoquinasa/metabolismo , Hiperglucemia/prevención & control , Resistencia a la Insulina/fisiología , Células Secretoras de Insulina/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Hiperglucemia/tratamiento farmacológico , Hiperglucemia/metabolismo , Insulina/metabolismo , Masculino , Ratones , Ratas , Ratas Zucker , Sulfonas/farmacología , Tiadiazoles/farmacologíaRESUMEN
BACKGROUND: 5'-Deoxy-5'-methylthioadenosine phosphorylase (MTAP) catalyzes the reversible phosphorolysis of 5'-deoxy-5'-methylthioadenosine (MTA) to adenine and 5-methylthio-D-ribose-1-phosphate. MTA is a by-product of polyamine biosynthesis, which is essential for cell growth and proliferation. This salvage reaction is the principle source of free adenine in human cells. Because of its importance in coupling the purine salvage pathway to polyamine biosynthesis MTAP is a potential chemotherapeutic target. RESULTS: We have determined the crystal structure of MTAP at 1.7 A resolution using multiwavelength anomalous diffraction phasing techniques. MTAP is a trimer comprised of three identical subunits. Each subunit consists of a single alpha/beta domain containing a central eight-stranded mixed beta sheet, a smaller five-stranded mixed beta sheet and six alpha helices. The native structure revealed the presence of an adenine molecule in the purine-binding site. The structure of MTAP with methylthioadenosine and sulfate ion soaked into the active site was also determined using diffraction data to 1.7 A resolution. CONCLUSIONS: The overall quaternary structure and subunit topology of MTAP are similar to mammalian purine nucleoside phosphorylase (PNP). The structures of the MTAP-ligand complexes provide a map of the active site and suggest possible roles for specific residues in substrate binding and catalysis. Residues accounting for the differences in substrate specificity between MTAP and PNP are also identified. Detailed information about the structure and chemical nature of the MTAP active site will aid in the rational design of inhibitors of this potential chemotherapeutic target. The MTAP structure represents the first structure of a mammalian PNP that is specific for 6-aminopurines.
Asunto(s)
Purina-Nucleósido Fosforilasa/química , Secuencia de Aminoácidos , Sitios de Unión , Catálisis , Cristalografía por Rayos X , Diseño de Fármacos , Inhibidores Enzimáticos , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Conformación Proteica , Estructura Secundaria de Proteína , Alineación de Secuencia , Especificidad por SustratoRESUMEN
C-terminal amidation is a posttranslational modification found in many neuropeptides. Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the synthesis of the biologically essential C-terminal amide from a glycine-extended precursor peptide. Reported herein are the first potent inhibitors of PAM. Dipeptides containing a C-terminal homocysteine and an N-acylated hydrophobic amino acid were found to inhibit PAM with IC50s in the low nanomolar range. Inhibition potency was dependent on both the carboxylate and the thiolate functionalities of the homocysteine and on the hydrophobic groups of the second amino acid. The thiolate was postulated to produce high binding affinities through coordination with the active-site copper. The compound series also exhibited potent inhibition of PAM in rat dorsal root ganglion cells as demonstrated by a dose-dependent increase in the substance P-Gly/substance P ratio. These results indicate that the compounds have sufficient potency and intracellular bioavailability to aid future studies focused on neuropeptide function and the contributions of neuropeptides to various disease processes.
Asunto(s)
Homocisteína/farmacología , Oxigenasas de Función Mixta/antagonistas & inhibidores , Complejos Multienzimáticos , Animales , Células Cultivadas , Homocisteína/análogos & derivados , Homocisteína/síntesis química , Ratas , Relación Estructura-Actividad , Sustancia P/biosíntesisRESUMEN
A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydronaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K(i) = 0.002 microM) is 10(5)-fold lower than the Km for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.
Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Azepinas/síntesis química , Inhibidores Enzimáticos/síntesis química , Imidazoles/síntesis química , AMP Desaminasa/química , Adenosina Desaminasa/química , Inhibidores de la Adenosina Desaminasa , Animales , Azepinas/química , Bovinos , Diseño de Fármacos , Inhibidores Enzimáticos/química , Humanos , Imidazoles/química , Relación Estructura-ActividadRESUMEN
AMP deaminase (AMPDA) inhibitors increase the levels of extracellular adenosine and preserve intracellular adenylate pools in cellular models of ATP depletion and therefore represent a potential new class of antiischemic drugs. Recently we reported that replacement of the ribose 5'-monophosphate component of the very potent transition-state analogue AMPDA inhibitor coformycin monophosphate (1) with a simple alkylcarboxy group resulted in potent, selective, and cell-penetrating AMPDA inhibitors. Here we report that replacement of this alkylcarboxy group with an alpha-substituted alkylmalonic acid resulted in enhanced inhibitor potency. The lead compound, 3-(5, 5-dicarboxy-6-(3-(trifluoromethyl)phenyl)-n-hexyl)coformycin aglycon (21), exhibited an AMPDA K(i) of 0.029 microM which is (3 x 10(5))-fold lower than the K(M) for the natural substrate AMP. A comparison of inhibitory potencies shows that the diacid analogues with alpha-benzyl substituents are 2-10-fold more inhibitory than similar monoacid-monoester, monoester-monoamide, or diester derivatives. Finally, these diacid analogues are 2-40-fold more potent inhibitors than the corresponding monocarboxylates.
Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Coformicina/análogos & derivados , Coformicina/síntesis química , Inhibidores Enzimáticos/síntesis química , Malonatos/síntesis química , Ribosa/química , AMP Desaminasa/química , Sitios de Unión , Coformicina/química , Inhibidores Enzimáticos/química , Malonatos/química , Imitación Molecular , Organofosfatos/química , Relación Estructura-ActividadRESUMEN
N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1, 3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)ethyl]-3,6,7,8-tetrahydroimidazo[4, 5-d][1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K(i) = 0. 06 microM. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.
Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Azepinas/síntesis química , Coformicina/análogos & derivados , Coformicina/síntesis química , Inhibidores Enzimáticos/síntesis química , Imidazoles/síntesis química , AMP Desaminasa/química , Azepinas/química , Coformicina/química , Inhibidores Enzimáticos/química , Imidazoles/química , Relación Estructura-ActividadRESUMEN
A series of N3-substituted coformycin aglycon analogues are described that inhibit adenosine 5'-monophosphate deaminase (AMPDA) or adenosine deaminase (ADA). The key steps involved in the preparation of these compounds are (1) treating the sodium salt of 6, 7-dihydroimidazo[4,5-d][1,3]diazepin-8(3H)-one (4) with an alkyl bromide or an alkyl mesylate to generate the N3-alkylated compound 5 and (2) reducing 5 with NaBH(4). Selective inhibition of AMPDA was realized when the N3-substituent contained a carboxylic acid moiety. For example, compound 7b which has a hexanoic acid side chain inhibited AMPDA with a K(i) = 4.2 microM and ADA with a K(i) = 280 microM. Substitution of large lipophilic groups alpha to the carboxylate provided a moderate potency increase with maintained selectivity as exemplified by the alpha-benzyl analogue 7j (AMPDA K(i) = 0.41 microM and ADA K(i) > 1000 microM). These compounds, as well as others described in this series of papers, are the first compounds suitable for testing whether selective inhibition of AMPDA can protect tissue from ischemic damage by increasing local adenosine concentrations at the site of injury and/or by minimizing adenylate loss.
Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Coformicina/análogos & derivados , Coformicina/síntesis química , Inhibidores Enzimáticos/síntesis química , AMP Desaminasa/química , Animales , Bovinos , Membrana Celular/metabolismo , Células Cultivadas , Coformicina/química , Coformicina/metabolismo , Endotelio/citología , Endotelio/metabolismo , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/metabolismo , Eritrocitos/metabolismo , Isquemia/prevención & control , Hígado/citología , Espectroscopía de Resonancia Magnética , Conejos , Ratas , Relación Estructura-ActividadRESUMEN
Inhibitors of the zinc protease neutral endopeptidase (NEP, EC 3.4.24.11) offer significant therapeutic interest as antihypertensives due to their ability to potentiate the biological action of the circulating natriuretic hormone ANF (atrial natriuretic factor). N-Phosphonomethyl dipeptides bearing a central (4-phenyl)phenylalanine residue have been designed to exert potent and selective NEP inhibition. In particular, (S)-3-[N-[2- [(phosphonomethyl)amino]-3-(4-biphenylyl)propionyl]amino]propionic acid (10a) (CGS 24592) displayed high inhibitory potency in vitro (IC50 = 1.9 +/- 0.1 nM) and a long plasma half-life in rats but lacked oral bioavailability. This drawback was overcome by using esterase-sensitive (acyloxy)alkyl phosphonates. More remarkable, several diaryl phosphonate derivatives of 10a also performed as effective prodrugs. Specifically, the structurally simple diphenyl phosphonate 18 (CGS 25462) induced potent inhibition of NEP ex vivo for at least 8 h after oral administration to rats (30 mg/kg). Its antihypertensive effect was demonstrated in DOCA-salt rats. At 30 mg/kg orally, 18 caused a significant reduction in mean arterial pressure measuring -35 +/- 7 mmHg at 5-h postdosing. The alpha-aminomethyl phosphonate 18 represents a new generation of selective NEP inhibitors that combine high potency, long duration of action, and oral bioavailability. Therefore, it holds promise as a novel therapeutic agent for the treatment of human hypertension and congestive heart failure.
Asunto(s)
Antihipertensivos/síntesis química , Compuestos de Bifenilo/síntesis química , Compuestos de Bifenilo/farmacología , Neprilisina/antagonistas & inhibidores , Organofosfonatos/síntesis química , Organofosfonatos/farmacología , Fenilalanina/análogos & derivados , Fosfopéptidos/síntesis química , Fosfopéptidos/farmacología , Profármacos/síntesis química , Profármacos/farmacología , Animales , Antihipertensivos/farmacocinética , Antihipertensivos/farmacología , Disponibilidad Biológica , Compuestos de Bifenilo/farmacocinética , Presión Sanguínea/efectos de los fármacos , Semivida , Organofosfonatos/farmacocinética , Fenilalanina/síntesis química , Fenilalanina/farmacocinética , Fenilalanina/farmacología , Fosfopéptidos/farmacocinética , Profármacos/farmacocinética , Ratas , Relación Estructura-ActividadRESUMEN
Adenosine receptor agonists produce a wide variety of therapeutically useful pharmacologies. However, to date they have failed to undergo successful clinical development due to dose-limiting side effects. Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Starting with 5-iodotubercidin (IC50 = 0.026 microM) and 5'-amino-5'-deoxyadenosine (IC50 = 0.17 microM) as lead inhibitors of the isolated human AK, a variety of pyrrolo[2,3-d]pyrimidine nucleoside analogues were designed and prepared by coupling 5-substituted-4-chloropyrrolo[2,3-d]pyrimidine bases with ribose analogues using the sodium salt-mediated glycosylation procedure. 5'-Amino-5'-deoxy analogues of 5-bromo- and 5-iodotubercidins were found to be the most potent AKIs reported to date (IC50S < 0.001 microM). Several potent AKIs were shown to exhibit anticonvulsant activity in the rat maximal electric shock (MES) induced seizure assay.
Asunto(s)
Adenosina Quinasa/antagonistas & inhibidores , Anticonvulsivantes/síntesis química , Inhibidores Enzimáticos/síntesis química , Tubercidina/análogos & derivados , Tubercidina/síntesis química , Animales , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Electrochoque , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Masculino , Ratas , Proteínas Recombinantes/antagonistas & inhibidores , Convulsiones/tratamiento farmacológico , Convulsiones/etiología , Relación Estructura-Actividad , Tubercidina/química , Tubercidina/farmacologíaRESUMEN
In the preceding article (Ugarkar et al. J. Med. Chem. 2000, 43) we reported that analogues of tubercidin are potent adenosine kinase (AK) inhibitors with antiseizure activity in the rat maximum electroshock (MES) model. Despite the discovery of several highly potent AK inhibitors (AKIs), e.g., 5'-amino-5'-deoxy- 5-iodotubercidin (1c) (IC50 = 0.0006 microM), no compounds were identified that exhibited a safety, efficacy, and side effect profile suitable for further development. In this article, we demonstrate that substitution of the tubercidin molecule with aromatic rings at the N4- and the C5-positions not only retains AKI potency but also improves in vivo activity. Synthesis of such compounds entailed transformation of 4-arylamino-5-iodotubercidin analogues to their corresponding 5-aryl derivatives via the Suzuki reaction. Alternatively, 4-N-arylamino-5-arylpyrrolo[2,3-d]pyrimidine bases were constructed and then glycosylated with appropriately protected alpha-ribofuranosyl chlorides using a phase-transfer catalyst. Several compounds exhibited potent activity in the rat MES seizure assay with ED50s < or = 2.0 mg/kg, ip, and showed relatively mild side effects.
Asunto(s)
Adenosina Quinasa/antagonistas & inhibidores , Anticonvulsivantes/síntesis química , Inhibidores Enzimáticos/síntesis química , Tubercidina/análogos & derivados , Tubercidina/síntesis química , Animales , Anticonvulsivantes/química , Anticonvulsivantes/farmacología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Espectroscopía de Resonancia Magnética , Ratas , Proteínas Recombinantes/antagonistas & inhibidores , Convulsiones/tratamiento farmacológico , Espectrofotometría Ultravioleta , Relación Estructura-Actividad , Tubercidina/química , Tubercidina/farmacologíaRESUMEN
X-ray crystallography and computer-assisted molecular modeling (CAMM) studies aided in the design of a potent series of mammalian purine nucleoside phosphorylase (PNP) inhibitors. Enhanced potency was achieved by designing substituted 9-(arylmethyl)-9-deazaguanine analogs that interact favorably with all three of the binding subsites of the PNP active site, namely the purine binding site, the hydrophobic pocket, and the phosphate binding site. The most potent PNP inhibitor prepared during our investigation, (S)-9-[1-(3-chlorophenyl)-2-carboxyethyl]-9-deazaguanine (18b), was shown to have an IC50 of 6 nM, whereas the corresponding (R)-isomer was 30-fold less potent.
Asunto(s)
Guanina/análogos & derivados , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Pirimidinas/síntesis química , Pirroles/síntesis química , Sitios de Unión , Simulación por Computador , Cristalografía por Rayos X , Guanina/química , Guanina/farmacología , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Fosfatos/metabolismo , Purinas/metabolismo , Pirimidinas/farmacología , Pirroles/farmacología , Relación Estructura-ActividadRESUMEN
9-(3,3-Dimethyl-5-phosphonopentyl)guanine was synthesized and found to be a potent inhibitor of purine nucleoside phosphorylase (PNP) (IC50 = 44 nM). A number of other functional end groups were investigated as phosphate mimics attached to the 9-position of guanine by this same alkyl side chain, which provided a sensitive method for the detection of any interaction of these groups with the phosphate binding site of PNP. Both the sulfonic acid (compound 13) and the carboxylic acid (compound 15) end groups interact significantly with the phosphate binding site, but in different ways, as determined by X-ray crystallographic analysis of the complexes. The sulfonic acid of 13, which binds about one-fourth as tightly as the phosphonate 12, binds in the phosphate subsite much like the phosphonic acid. The carboxylic acid, the interaction of which is much weaker, turns away from the center of the phosphate binding site to form hydrogen bonds with Ser 200 and Met 219. Thus, the only phosphate mimics that bind like phosphate itself are themselves highly ionic, probably with limited ability to penetrate cell membranes.
Asunto(s)
Guanina/análogos & derivados , Fosfatos/metabolismo , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Sitios de Unión , Ácidos Carboxílicos/química , Ácidos Carboxílicos/metabolismo , Simulación por Computador , Cristalografía por Rayos X , Guanina/síntesis química , Guanina/metabolismo , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Fosfatos/química , Purina-Nucleósido Fosforilasa/química , Purina-Nucleósido Fosforilasa/metabolismo , Relación Estructura-Actividad , Ácidos Sulfónicos/química , Ácidos Sulfónicos/metabolismoRESUMEN
Alicyclic and heteroalicyclic derivatives of 9-deazaguanine (2-amino-1,5-dihydro-4H-pyrrolo[3,2-d] [pyrimidin-4-one) are, with one exception, potent inhibitors of purine nucleoside phosphorylase (PNP) equaling the corresponding 9-arylmethyl derivatives previously investigated. The mode of binding of these compounds to PNP was determined by X-ray crystallography.
Asunto(s)
Guanina/análogos & derivados , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Sitios de Unión , Cicloparafinas/síntesis química , Cicloparafinas/farmacología , Diseño de Fármacos , Guanina/síntesis química , Guanina/metabolismo , Guanina/farmacología , Modelos Moleculares , Conformación Molecular , Método de Montecarlo , Unión Proteica , Purina-Nucleósido Fosforilasa/metabolismo , Relación Estructura-Actividad , Termodinámica , Difracción de Rayos XRESUMEN
Purine nucleoside phosphorylase (PNP, EC 2.4.2.1) is a salvage enzyme important to the T-cell-mediated part of the immune system and as such is an important therapeutic target. This paper describes the design, synthesis, and enzymatic evaluation of potent, competitive inhibitors of PNP. Potential inhibitors were designed using the three-dimensional structure of the enzyme in an iterative process that involved interactive computer graphics to model the native enzyme and complexes of it with the inhibitors, Monte Carlo-based conformational searching, and energy minimization. Studies of the enzyme/inhibitor complexes were used to determine priorities of the synthetic efforts. The resulting compounds were then evaluated by determination of their IC50 values and by X-ray diffraction analysis using difference Fourier maps. In this manner, we have developed a series of 9-(arylmethyl)-9-deazapurines (2-amino-7-(arylmethyl)-4H-pyrrolo[3,2-d]-pyrimidin-4-ones) that are potent, membrane-permeable inhibitors of the enzyme. The IC50 values of these compounds range from 17 to 270 nM (in 1 mM phosphate), with 9-(3,4-dichlorobenzyl)-9-deazaguanine being the most potent inhibitor. X-ray analysis explained the role of the aryl groups and revealed the rearrangement of hydrogen bonds in the binding of the 9-deazaguanines in the active site of PNP relative to the binding of the 8-aminoguanines that results in more potent inhibition of the enzyme.
Asunto(s)
Guanina/análogos & derivados , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Animales , Sitios de Unión , Bovinos , Cristalografía , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/metabolismo , Guanina/metabolismo , Guanina/farmacología , Cinética , Relación Estructura-ActividadRESUMEN
The potencies of thiorphan and phosphoramidon as inhibitors of neutral endopeptidase 24.11 (NEP) are significantly affected by pH. Thiorphan and phosphoramidon are 10- and 150-fold more potent, respectively, when measured at pH 6.5 than at pH 8.5. The kinetic characteristics of these two inhibitors are different. NEP activity is readily inhibited by phosphoramidon upon mixing, while thiorphan becomes a more potent inhibitor only after preincubation with the enzyme.
Asunto(s)
Glicopéptidos/farmacología , Riñón/enzimología , Neprilisina/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Tiorfan/farmacología , Animales , Concentración de Iones de Hidrógeno , Masculino , Ratas , Ratas Endogámicas , Factores de TiempoRESUMEN
Substance P has been implicated as a mediator of inflammation. The involvement of this neuropeptide in carrageenan-induced hind paw edema in the rat was assessed. Subcutaneous injection of carrageenan into the rat paw caused a significant increase in substance P levels, which preceded the onset of inflammation. While injection of substance P alone caused mild edema, coadministration of submaximal doses of carrageenan and substance P resulted in a synergistic exacerbation in the degree of inflammation. This synergistic response was not detected when the nonamidated precursor of substance P was coinjected with carrageenan. The effects of substance P depletion on inflammation were also evaluated. In animals pretreated with capsaicin followed by injection with carrageenan, no significant increase in either the levels of substance P or the extent of edema was observed when compared to capsaicin-treated controls. These results indicate that substance P may play an important role in the early stages of carrageenan-induced paw edema and that a reduction in the biosynthesis of substance P may lessen the severity of this inflammatory response.
Asunto(s)
Carragenina , Edema/inducido químicamente , Pie , Sustancia P/farmacología , Animales , Capsaicina/farmacología , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Edema/metabolismo , Edema/patología , Femenino , Pie/patología , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Sustancia P/metabolismoRESUMEN
A major milestone in purine metabolism research has been achieved with the discovery of these potent and selective AMPDA inhibitors. These inhibitors of AMPDA are based on carboxypentyl substitution on N-3 of the coformycin aglycon. They are simpler than coformycin ribose 5'-monophosphate, more stable, selective against other AMP binding enzymes as well as ADA and have good cell penetration and good oral bioavailability. These compounds and their more potent analogs are the first compounds with suitable characteristics to allow a definitive analysis of the role of AMPDA in cellular metabolism and AMPDA as a therapeutic target.
Asunto(s)
AMP Desaminasa/antagonistas & inhibidores , Coformicina/análogos & derivados , Coformicina/química , Inhibidores Enzimáticos/química , Administración Oral , Disponibilidad Biológica , Coformicina/síntesis química , Coformicina/farmacocinética , Diseño de Fármacos , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/farmacocinética , Humanos , Modelos Moleculares , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Structure-activity studies have been performed to optimize the potency of this novel series of AMPDA inhibitors. Conformational rigidification of the N-3 sidechain resulted in substantial effect on the potency. Addition of the hydrophobic groups provided further benefit. The most potent compound identified, 4g (Ki = 3 nM), bears little structural resemblance to AMP and exhibits a remarkable improvement (10(3) and 10(5)) in binding affinity relative to the original lead and AMP, respectively. The application of prodrug strategy achieved a large improvement (benzyl ester 5d) in oral bioavailability, resulting in compounds that should be useful in evaluating the role of AMPDA in normo- and pathophysiological states.